A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Defining the future of pharmaceutical quality control We are leading a global transformation toward fully automated microbial quality control within pharmaceutical manufacturing. Our products safeguard the most complex and critical bioprocessing workflows in the industry, enabling faster, safer, and higher capacity drug production. Through our unique expertise at the intersection of microbiology, robotic systems, and advanced vision algorithms, we are setting the foundation for end-to-end quality control automation to enable the future of advanced pharmaceutical manufacturing. We are an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics and cell and gene therapies, vaccines, and sterile injectables.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 31M | 28M | - | - | - | 16M |
| Net Income | -44M | -47M | -52M | -61M | -78M | - |
| EPS | $-1.00 | $-1.08 | $-1.22 | $-1.43 | $-3.94 | $-126.11 |
| Free Cash Flow | -39M | -46M | -47M | -65M | -58M | -32M |
| ROIC | -163.7% | -62.1% | -44.4% | -37.0% | -35.3% | - |
| Gross Margin | 29.4% | 25.0% | - | - | - | - |
| Debt/Equity | 0.42 | 0.00 | 0.00 | 0.00 | 0.00 | -0.20 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -45M | -50M | -57M | -63M | -47M | -31M |
| Operating Margin | -148.8% | -178.0% | - | - | - | -190.0% |
| ROE | -99.9% | -48.5% | -44.5% | -37.0% | -166.1% | - |
| Shares Outstanding | 40M | 43M | 43M | 43M | 20M | - |
| Metric | 2020 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 16M | N/A | N/A | N/A | 28M | 31M |
| Gross Margin | N/A | N/A | N/A | N/A | 25.0% | 29.4% |
| R&D | 6.5M | 9.8M | 13M | 13M | 15M | 14M |
| SG&A | 10.0M | 18M | 27M | 25M | 22M | 22M |
| EBIT | -31M | -47M | -63M | -57M | -50M | -45M |
| Op. Margin | -190.0% | N/A | N/A | N/A | -178.0% | -148.8% |
| Net Income | N/A | -78M | -61M | -52M | -47M | -44M |
| Net Margin | N/A | N/A | N/A | N/A | -167.2% | -145.1% |
| Non-Recurring | 154K | 18K | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | N/A | -35.3% | -37.0% | -44.4% | -62.1% | -163.7% |
| ROE | N/A | -166.1% | -37.0% | -44.5% | -48.5% | -99.9% |
| ROA | N/A | -50.2% | -31.9% | -36.6% | -38.8% | -52.5% |
| Cash Flow | ||||||
| Op. Cash Flow | -31M | -55M | -59M | -45M | -44M | -38M |
| Free Cash Flow | -32M | -58M | -65M | -47M | -46M | -39M |
| Owner Earnings | -33M | -58M | -65M | -53M | -51M | -45M |
| CapEx | 690K | 3.2M | 6.7M | 1.8M | 1.4M | 856K |
| Maint. CapEx | 1.5M | 1.5M | 2.8M | 3.1M | 3.4M | 3.3M |
| Growth CapEx | 0 | 1.7M | 3.9M | 0 | 0 | 0 |
| D&A | 1.5M | 1.5M | 2.8M | 3.1M | 3.4M | 3.3M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 533K | 1.8M | 4.0M | 4.8M | 3.9M | 4.1M |
| Debt Repayment | 18M | 26M | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||
| Net Debt | -20M | -193M | -109M | -92M | -51M | -22M |
| Cash & Equiv. | 30M | 178M | 27M | 24M | 17M | 41M |
| Long-Term Debt | 25M | 0 | 0 | 262K | 170K | 19M |
| Debt/Equity | -0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.42 |
| Interest Coverage | -8.9 | -17.8 | -1505.2 | -13.4 | -15.8 | -15.8 |
| Equity | -127M | 221M | 164M | 118M | 75M | 44M |
| Total Assets | 70M | 241M | 191M | 143M | 98M | 84M |
| Total Liabilities | 45M | 20M | 26M | 25M | 23M | 40M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -242M | -315M | -376M | -428M | -475M | -510M |
| Working Capital | 47M | 200M | 120M | 101M | 63M | 53M |
| Current Assets | 62M | 218M | 139M | 120M | 81M | 70M |
| Current Liabilities | 16M | 18M | 19M | 19M | 18M | 17M |
| Per Share Data | ||||||
| EPS | -126.11 | -3.94 | -1.43 | -1.22 | -1.08 | -1.00 |
| Owner EPS | N/A | -2.95 | -1.54 | -1.23 | -1.18 | -1.13 |
| Book Value | N/A | 11.16 | 3.86 | 2.74 | 1.74 | 1.11 |
| Cash Flow/Share | N/A | -2.78 | -1.38 | -1.05 | -1.02 | -1.03 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | N/A | 19.8M | 42.5M | 43.0M | 43.4M | 39.8M |
| Valuation | ||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | -2.2 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 0.9 | 0.3 | 0.3 | 0.6 | 2.0 |
| Price/Sales | N/A | N/A | N/A | N/A | 1.4 | 2.9 |
| FCF Yield | N/A | -30.4% | -116.3% | -124.7% | -109.4% | -44.2% |
| Market Cap | N/A | 192M | 56M | 38M | 42M | 87M |
| Avg. Price | N/A | 18.14 | 4.68 | 1.08 | 0.90 | 2.19 |
| Year-End Price | N/A | 9.67 | 1.32 | 0.88 | 0.96 | 2.19 |
RAPID MICRO BIOSYSTEMS, INC. passes 0 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 25.0%.
RAPID MICRO BIOSYSTEMS, INC. (RPID) has a 5-year average return on invested capital (ROIC) of -44.7%. This is below average and may indicate limited pricing power.
RAPID MICRO BIOSYSTEMS, INC. (RPID) has a market capitalization of $87M. It is classified as a small-cap stock.
RAPID MICRO BIOSYSTEMS, INC. (RPID) does not currently pay a regular dividend.
RAPID MICRO BIOSYSTEMS, INC. (RPID) operates in the Laboratory Analytical Instruments industry, within the Technology sector.
RAPID MICRO BIOSYSTEMS, INC. (RPID) reported annual revenue of $28 million in its most recent fiscal year, based on SEC EDGAR filings.
RAPID MICRO BIOSYSTEMS, INC. (RPID) has a net profit margin of -167.2%. The company is currently unprofitable.
RAPID MICRO BIOSYSTEMS, INC. (RPID) generated $-46 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
RAPID MICRO BIOSYSTEMS, INC. (RPID) has a debt-to-equity ratio of 0.00. This indicates a conservatively financed balance sheet.
RAPID MICRO BIOSYSTEMS, INC. (RPID) reported earnings per share (EPS) of $-1.08 in its most recent fiscal year.
RAPID MICRO BIOSYSTEMS, INC. (RPID) has a return on equity (ROE) of -48.5%. A negative ROE may indicate losses or negative equity.
RAPID MICRO BIOSYSTEMS, INC. (RPID) has a 5-year average gross margin of 25.0%. This lower margin is typical of capital-intensive or commodity businesses.
The Ledger Terminal provides 5 years of financial data for RAPID MICRO BIOSYSTEMS, INC. (RPID), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
RAPID MICRO BIOSYSTEMS, INC. (RPID) has a book value per share of $1.74, based on its most recent annual SEC filing.